ALEXION ILAC TICARET LIMITED SIRKETI

ALEXION ILAC TICARET LIMITED SIRKETI is a trading company.

Company Introduction:

ALEXION ILAC TICARET LIMITED SIRKETI is the Turkish subsidiary of Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering, developing, and delivering life-changing medicines for people with rare diseases. The company's operations in Turkey are primarily commercial, serving as a trading and distribution arm for Alexion's specialized pharmaceutical products. Its main activities include the marketing, sales, and distribution of innovative therapies across the Turkish market.

The company is dedicated to ensuring that patients in Turkey suffering from severe and ultra-rare conditions have access to Alexion's essential treatments. It handles market access strategies, regulatory affairs, commercial operations, and patient support programs to bring groundbreaking medicines to those who need them. While its parent company, Alexion Pharmaceuticals, engages in extensive research and manufacturing globally, ALEXION ILAC TICARET LIMITED SIRKETI's role in Turkey is centered on the commercialization and distribution of these pharmaceutical products, rather than local manufacturing.

Here are some of the products manufactured or marketed by ALEXION ILAC TICARET LIMITED SIRKETI in Turkey:

* Soliris (eculizumab)

* Ultomiris (ravulizumab)

* Strensiq (asfotase alfa)

* Kanuma (sebelipase alfa)

Please note that product availability may vary.